Measles, Rubella and Congenital Rubella Syndrome (CRS) Country Profile

Barbados

Pan American Health Organization

Introduction

The measles and rubella country profile aims to facilitate the analysis of data compiled in the last five years. This profile was only developed for those countries who officially reported vaccination coverage and case by case surveillance and laboratory data to the Pan American Health Organization (PAHO). There may be minor differences in the country profile if the country has updated data that was not reported to PAHO. The country profile will be automatically updated twice per year: at the end of April (surveillance data) and at the end of September (vaccination coverage data).

General Information

Table 1: Demographic data, 2022.

Demographic group	Population
1 year of age	3,013
Total population	281,661

Table 2: Last endemic cases by year and disease.

Measles	Rubella	CRS
1991	1999	1997

Table 3: Vaccination schedule.

Vaccine	1st Dose	2nd Dose	MMR2 Year Introduced
MMR	12 mo	18 mo	1997

Epidemiology and Quality of Surveillance

Figure 1: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.




Table 4: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected MR cases Suspected MR notification rate per 100,000 population		10		4 1 42	7 2.49

Figure 2: Distribution of suspected CRS cases and notification rate at the national level, 2018- 2022.




Table 5: Distribution of suspected CRS cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected CRS cases	0	0	0	0	0
Suspected CRS notification rate per 10,000 live births	0	0	0	0	0

Figure 3: Reported cases of measles and rubella by epidemiological week and final classification: confirmed, discarded and under investigation, 2018-2022.






Table 6: Reported cases of measles and rubella by epidemiological year and final classification, 2018-2022.

Classification	2018	2019	2020	2021	2022
Confirmed (Measles)	0	0	0	0	0
Confirmed (Rubella)	0	0	0	0	0
Pending	0	0	0	0	0
Discarded	11	13	12	4	7
Total	11	13	12	4	7

Figure 4: Distribution of reported measles and rubella cases and incidence rate by age group, 2018-2022.








Table 7: Municipalities reporting measles and rubella suspected cases by year, 2018-2022.


	No. of municipalities	Total municipalities in	% of municipalities reporting
Year	reporting suspected cases	the country	suspected cases
2018	1	10	10
2019	1	10	10
2020	0	10	0
2021	NA	10	NA
2022	0	10	0

Laboratory Surveillance

Table 8: Criteria used to discard suspected measles and rubella cases by year, 2018-2022.

			Criteria	a for discard	ling	No.	of cases disc	carded by o	ther differe	ntial diagno	osis
Year	No. of suspected cases reported	No. of discarded cases	IgM Negative	No data	Others	Vaccine reaction	Dengue	Parvo virus	Herpes 6	Allergic reaction	Others
2018	11	11	8	0	3	1	0	0	0	0	2
2019	13	13	13	0	0	0	0	0	0	0	0
2020	12	12	12	0	0	0	0	0	0	0	0
2021	4	4	3	0	1	0	0	0	0	0	1
2022	7	7	7	0	0	0	0	0	0	0	0

Figure 6: Distribution of discarded measles and rubella suspected cases by other differential diagnosis, 2018-2022.



Analysis of Vaccination Coverage and Population Cohorts

Figure 7: Coverage of the first dose of measles-mumps-rubella (MMR1) vaccine, number of doses administered, and number of children 1 year of age, 2018-2022.




Figure 8: Coverage of the second dose of measles-mumps-rubella (MMR2) vaccine, number of doses administered, and number of children 18 month(s) of age, 2018-2022.






Table 9: Vaccination coverage with first and second dose of measles-mumps-rubella (MMR1 and MMR2) vaccines by target population and administered doses, 2018-2022.

		MMR1			MMR2	
Year	Administered doses	Target population	Coverage	Administered doses	Target population	Coverage
2018	2,060	2,434	85	1,811	2,434	74
2019	2,418	2,384	100	2,016	2,384	85
2020	$2,\!256$	2,524	89	1,978	2,524	78
2021	1,825	2,384	77	1,667	2,384	70
2022	1,925	2,263	85	1,662	2,263	73

Figure 9: Subnational coverage of the first dose of measles-mumps-rubella (MMR1) vaccine and proportion of children aged 1 year, 2021











Figure 11: Proportion of children living in those municipalities for MMR1 vaccination coverage ranges, 2018-2022.








Figure 13: Proportion of children living in those municipalities for MMR2 vaccination coverage ranges, 2018-2022.




Table 10: Proportion of municipalities with MMR1 and MMR2 coverage ranges and proportion of children living in those municipalities, 2018-2022.

		MN	IR1	MN	IR2
Year	Coverage range (%)	MMR1	MMR2	MMR1	MMR2
2022	<80	70	80	64.3	75.5
2022	80-89	10	0	11.2	0.0
2022	90-94	10	10	3.7	3.7
2022	95-100	0	0	0.0	0.0
2022	>100	10	10	20.9	20.9
2021	< 80	80	90	75.0	79.0
2021	80-89	10	0	4.0	0.0
2021	90-94	0	10	0.0	21.0

	3.0
	1.0 3.0 0
	0 7.2).0
	1.6 1.2 0
2018 80-89 40 30 25.2 13 2018 90-94 10 10 12.6 13	3.5 5.7 2.6 3.2

References

Section	Sources
General Information	[1] United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Epidemiology and Quality of Surveillance	Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Laboratory Surveillance	Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO.
Analysis of Vaccination Coverage and Population Cohorts	[2] Country reports through the electronic PAHO-WHO/UNICEF Joint Reporting Form (eJRF).